Livforsakringsbolaget Skandia Omsesidigt Makes New $1.21 Million Investment in Thermo Fisher Scientific Inc. $TMO

Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 2,419 shares of the medical research company’s stock, valued at approximately $1,212,000.

A number of other hedge funds have also made changes to their positions in TMO. Rakuten Investment Management Inc. bought a new position in Thermo Fisher Scientific during the 2nd quarter valued at about $30,810,000. Glenview Trust Co bought a new position in shares of Thermo Fisher Scientific in the second quarter valued at approximately $12,696,000. North Star Asset Management Inc. acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth approximately $30,456,000. Empowered Funds LLC bought a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $18,247,000. Finally, United Capital Financial Advisors LLC bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at $24,312,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the topic of several research analyst reports. HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their target price for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. Morgan Stanley upped their price target on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. Jefferies Financial Group reissued a “buy” rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Finally, Stifel Nicolaus set a $650.00 price objective on Thermo Fisher Scientific in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $619.41.

Insider Buying and Selling

In related news, EVP Michael D. Shafer sold 25,500 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president owned 20,994 shares in the company, valued at $12,596,400. This represents a 54.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the transaction, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. This represents a 1.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 73,768 shares of company stock worth $44,122,820 over the last ninety days. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $621.87 on Friday. The stock has a market cap of $229.94 billion, a P/E ratio of 33.45, a price-to-earnings-growth ratio of 2.53 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $647.00. The stock’s 50-day moving average price is $558.64 and its two-hundred day moving average price is $512.08. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same period last year, the company posted $4.28 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.